Alphamab Oncology (STU:3NK) Dividends per Share : €0.00 (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Dividends per Share?

Alphamab Oncology's dividends per share for the six months ended in Dec. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2024 was 0.00. As of today, Alphamab Oncology's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Alphamab Oncology Dividends per Share Historical Data

The historical data trend for Alphamab Oncology's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Dividends per Share Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Dividends per Share	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Alphamab Oncology's Dividends per Share

For the Biotechnology subindustry, Alphamab Oncology's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Alphamab Oncology Dividends per Share Calculation

Dividends paid to per common share.

Alphamab Oncology (STU:3NK) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Alphamab Oncology's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	0.029
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Alphamab Oncology Dividends per Share Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

09966:Hong Kong

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines